Document:

Exhibit 10.3

 

CONFIDENTIAL
TREATMENT REQUESTED

WITH
RESPECT TO CERTAIN PORTIONS HEREOF

DENOTED
WITH “***”

 

 

 

AMENDED SUPPLY AGREEMENT

 

his
Amended Supply Agreement ("Agreement") is hereby made effective on this _17_ day of November, 2016 ("Effective
Date"), by and between Myos Rens
Technology Inc., a Nevada corporation, having an address of 45 Horsehill Road, Cedar Knolls, NJ 07927 (hereinafter "Customer")
and DIL Technologie GmbH, a German company having a business address of Prof.-von-Klitzing-Str . 7, D - 49610 Quakenbrtick, Germany
(hereinafter "Manufacturer"), and is intended to supersede and replace the
First Amended and Restated Exclusive Supply Agreement entered into on July 15, 2014, which amended and replaced the Exclusive
Supply Agreement entered into between the Parties on June 24, 2013.

WHEREAS,
the Parties agree as follows:

1.
WORK

Manufacturer
agrees to use its best efforts to perform the work (hereinafter "Work") pursuant to continuous and regular supply terms
discussed and agreed upon between the Parties, as initially determined herein. The Parties agree Work shall mean the manufacturing,
packaging and exportation of fertilized chicken egg yolk, via a patented process and form as defined in Exhibit A (the "Product").

2.
REQUIREMENTS FOR PURCHASING

Commencing
in January 2017, Customer shall pay Manufacturer €10,000 per month until Customer resumes ordering Product from Manufacturer.
The €10,000 per month payment shall cease upon the Customer issuance to the Manufacturer of a written purchase order or December
31, 2018, whichever occurs first. . Customer and Manufacturer agree to establish a research program that Manufacturer shall conduct
on behalf of Customer's research needs, in exchange for these monthly payments.

Customer
will provide to Manufacturer [***] months advance notice for future purchase orders
of the Products. Any order must be for at least of [***] kg per month for a minimum period of [***] months.

The
Parties agree that Manufacturer shall only manufacture, the Product for Customer or for Customer's commercial benefit, subject
to the terms and conditions specified in Section 5.1.2. This grant of exclusivity by
Manufacturer to Customer is granted in perpetuity. Nothing herein shall preclude Manufacturer from using Product for non-commercial
purposes to further its own research advancements.

3.
SHIPMENTS

All
Products delivered pursuant to the terms of this Agreement shall be suitably packed for shipment in
accordance with industry standards in sealed containers/bags, marked for shipment to Customer's requested destination, and
delivered to a carrier or forwarding agent, as determined by Customer. Shipment will be F.O.B at Manufacturer, or
Manufacturer's designated facility, and all freight, insurance, and other shipping expenses, as well as any special packing
expenses not included in the original price quotation for the Products will be paid by Customer.

    	 	1	 

    	 

    

CONFIDENTIAL
TREATMENT REQUESTED

WITH
RESPECT TO CERTAIN PORTIONS HEREOF

DENOTED
WITH “***”

 

4.
cGMP COMPLIANCE, CERTIFICATE OF ANALYSIS AND WARRANTIES

4.1
cGMP Compliance

Manufacturer
agrees that all Products made hereunder shall be manufactured in accordance with cGMP Compliance standards. In
particular, Manufacturer agrees to comply with cGMP batch record keeping standard as set forth by German Good Manufacturing
Practice standards for foodstuffs. The Parties agree the resulting Product or Blended Product shall also be in specific compliance
with the standards set forth in Exhibits C and D, respectively.

4.2
Certificate of Analysis

Manufacturer
agrees to perform the necessary testing and analysis for each batch of Product or Blended Product manufactured and provide Customer
with a Certificate of Analysis therewith. Such Certificate of Analysis for each batch shall include test results for various parameters
listed in Exhibits C and D. Such Certificate of Analysis shall be signed and certified by a qualified employee of Manufacturer.

 4.3 Certificate of Veterinarian

Manufacturer
agrees to obtain the necessary certifications from a licensed German veterinarian for each batch of Product manufactured for purposes
of exporting the Product from the European Union. Customer shall notify Manufacturer of the requisite certification standards
pertaining to the importation of egg-based products from the European Union into the United States.

4.4
Express Warranty

(a)  
Manufacturer warrants that the Product will conform to all applicable product specifications as set forth herein and will
be free from contamination, i.e., under the threshold limits established in Exhibit C and Exhibit D.

(b) 
Upon any failure of a Product to comply with any and all applicable warranties, the Manufacturer shall promptly replace
such quantity of Product at no additional cost, within thirty (60) days of written notification of such failure.

5.
PAYMENT TERMS, PRODUCT PRICING & CASH UPON SIGNING

5.1
PAYMENT TERMS

5.1.1
Human Application

    	 	2	 

    	 

    

CONFIDENTIAL
TREATMENT REQUESTED

WITH
RESPECT TO CERTAIN PORTIONS HEREOF

DENOTED
WITH “***”

 

Customer
agrees to pay Manufacturer €400,000 in exchange for the satisfaction of all prior terms duties, liabilities and obligations
as set forth in the First Amended and Restated Exclusive Supply Agreement dated July 15, 2014, including, but not limited to,
all of the terms, duties, liabilities and obligations set forth in Sections 6.2, 6.2.1 and 6.2.2 of that Agreement. The Parties
hereby agree and acknowledge that all prior terms duties, liabilities and obligations of both Parties as set forth in the First
Amended and Restated Exclusive Supply Agreement dated July 15, 2014 have been fully satisfied.

Payment
shall be made as follows: Customer agrees to pay Manufacturer €400,000 within ten (10) days of the execution of this
Agreement; for acquiring the exclusive rights outside the United States for
Manufacturer to exclusively manufacture, develop and produce Products for Customer for human application.

5.1.2       Domesticated
Animals Pet Application

Customer
agrees to pay Manufacturer €[***] for a one (1)-year option commencing on January
1, 2017 for Customer to develop a strategic plan for Products for domesticated animals pet sector outside the United States. By
exercising this option, Customer has the right to pay an additional €[***], within [***] year, to Manufacturer to acquire
the exclusive rights outside the United States for Manufacturer to exclusively manufacture, develop and produce Product for Customer
in the domesticated animals pet sector. During this [***] year period, Manufacturer shall not enter into any negotiation or agreement
with a third party relating to the use of Product in the domesticated animal pet sector. Domesticated animals shall hereby be
defined to be household pets such as cats and dogs.

5.2
PRODUCT PRICING

Commencing
on the Effective Date, the Parties agree the price per kilogram of Product shall be [***] Euros ([***]€). Manufacturer shall
use its best efforts to reduce such price through cost savings with its vendors, which it shall pass through to Customer.

 

6.
INTELLECTUAL PROPERTY RIGHTS

 

Manufacturer
is the owner of European Patent No. 12171561 (the "EP Patent"), which
covers substantially similar subject matter as the U.S. Application, and as of the Effective Date, is valid in several
European jurisdictions . The Parties agree, in the event a third party expresses bona fide interest in EU Patent for human
application only (i.e., either to license or acquire the EU Patent) and Manufacturer agrees in principal to the same, at any
time during the validity of the EU Patent, Manufacturer shall notify Customer of the same in writing, and
shall offer Customer a right of first refusal to any potential transaction involving the EU Patent for human
application only. Customer shall have one hundred twenty (120) days from the receipt of the written notice to review,
analyze, and consider accepting its right of first refusal to such terms for the EU Patent. Manufacturer agrees any
assignment or licensing of rights to the EU Patent to any third party for human application only, without following the right
of first refusal terms herein, shall render such assignment or license null and void.

    	 	3	 

    	 

    

CONFIDENTIAL
TREATMENT REQUESTED

WITH
RESPECT TO CERTAIN PORTIONS HEREOF

DENOTED
WITH “***”

 

If
Manufacturer files patent applications or procure patent rights covering substantially similar subject matter as the EP Patent
or the U.S. Application in other jurisdictions, the Parties agree that, Customer shall be offered the same right of first refusal
to any potential transaction involving a third party's expression of a bona fide interest in the worldwide patent rights for human
application.

 

7.
TERM AND TERMINATION

7.1
Term

The
term of this Agreement shall commence on the Effective Date, and shall continue through December
31, 2018. Upon request from Customer, this Agreement may be renewed for subsequent one year terms indefinitely unless terminated
by Customer upon giving sixty (60) days written notice prior to the expiration of any renewal term.

7.2
Termination

This
Agreement may only be terminated by either party for cause upon written notice to the other party of a material breach hereof,
or upon written agreement of the Parties. Upon receipt of such notification, the breaching party shall be permitted Sixty (60)
days to cure any such breach. If after such sixty (60) days period
the breaching party has not cured such breach, then the non breaching party may terminate this Agreement immediately upon sending
written notification of the same to the breaching party. Termination of this Agreement shall not affect the obligations of either
Party that exist as of the date of termination.

8.
LIMITATIONS OF LIABILITY

8.1
Patents, Copyrights, Trade Secrets, Other Proprietary Rights

Each
Party ("Indemnifying Party") shall defend, indemnify, and hold harmless the other Party ("Indemnified Party")
from all claims, costs, damages, judgments, and attorney's fees resulting from or arising out of any alleged and/or actual infringement
or other violation of intellectual property rights in connection with the performance by the Indemnifying Party of its obligations
under this Agreement ("Intellectual Property Rights"). The Indemnified Party shall promptly notify the Indemnifying
Party in writing of the initiation of any such claims. In the event of any litigation, suit or other proceedings relating to or
concerning such Intellectual Property Rights, the Indemnified Party shall permit the Indemnifying Party to assume the defense
thereof, and cooperate with the Indemnifying Party with respect to such defense. If
the Indemnifying Party elects not to assume the defense, the Indemnified Party shall have the right to seek, and have the
Indemnifying Party pay for separate counsel representing the interests of Indemnified Party.
Further, any and all settlements regarding such Intellectual Property Rights shall be approved in writing by an authorized
representative of Indemnified Party.

    	 	4	 

    	 

    

CONFIDENTIAL
TREATMENT REQUESTED

WITH
RESPECT TO CERTAIN PORTIONS HEREOF

DENOTED
WITH “***”

 

THE
FOREGOING STATES THE ENTIRE LIABILITY OF THE PARTIES TO EACH OTHER CONCERNING INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS.

 

8.2
No Other Liability

 

INDEPENDENT
OF OR UNDER THE EXPRESS WARRANTIES CREATED UNDER THIS AGREEMENT, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR
ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, OR PUNITIVE DAMAGES OF ANY KIND OR NATURE ARISING OUT OF THIS AGREEMENT OR THE
SALE OF PRODUCTS, WHETHER SUCH LIABILITY IS ASSERTED ON THE BASIS OF CONTRACT, TORT (INCLUDING THE POSSIBILITY OF NEGLIGENCE,
INTENTIONAL MISCONDUCT OR STRICT LIABILITY), OR OTHERWISE, EVEN IF
THE ONE PARTY HAS BEEN WARNED OF THE POSSIBILITY OF ANY SUCH LOSS OR DAMAGE, AND
EVEN IF ANY OF THE LIMITED REMEDIES IN THIS AGREEMENT FAIL OF THEIR ESSENTIAL PURPOSE, IT BEING ACKNOWLEDGED BY THE PARTIES
THAT THIS LIMITATION OF LIABILITY IS ESSENTIAL CONSIDERATION FOR ENTERING INTO AND PERFORMANCE OF THIS
AGREEMENT.

8.3
Customer Responsible for U.S. Liability

Notwithstanding
any of the above paragraphs, and for the avoidance of doubt, with the exception of
willful or intentional acts or gross misconduct of Manufacturer, Customer shall be responsible for any liability occurring within
the United States, arising from Manufacturer's manufacture of Products in accordance with the terms of this Agreement.

9.
MISCELLANEOUS

9.1
Entire Agreement

This
Agreement constitutes the entire agreement between the parties with respect to the transactions contemplated hereby and supersedes
all prior agreements and understandings between the parties relating to such transactions, unless such prior agreements are expressly
identified herein as remaining in
full force and effect. Each Party shall hold the existence and terms of this Agreement confidential, unless it obtains
the other Party's express written consent otherwise, provided that Manufacturer
may use Customer's name as a reference unless otherwise instructed in writing by
Customer.

9.2
Amendments

This
Agreement may be amended only by a writing executed by authorized representatives of both parties.

    	 	5	 

    	 

    

 

9.3
Independent Contractor

Neither
party shall, for any purpose, be deemed to be an agent of the other party; the relationship between the parties only be that of
independent contractors. Neither party shall have any right or authority to assume or create any obligations or to make any representations
or warranties on behalf of any other party, whether express or implied, or to bind
the other party in any respect whatsoever.

9.4
Expenses

 

In
the event a dispute between the parties hereunder with respect to this Agreement must be resolved by litigation or other
proceeding or a party must engage an attorney to enforce its right hereunder, the prevailing party shall be entitled to receive
reimbursement for all associated reasonable costs and expenses (including, without limitation, attorney's fees) from the other
party.

9.5
Governing Law

This
Agreement shall be governed by and construed under the laws of the United States.

 

9.6
Assignment

 

(a)             
Neither party shall assign or transfer this Agreement, except as expressly
provided herein, without the prior written consent of the other party; provided, however,
that a Party may transfer or assign its rights and obligations under this Agreement in connection with a merger, reorganization,
consolidation or sale of all or substantially all of its assets.

(b)            
This Agreement shall be binding upon and inure to the benefit of the parties'
successors and assigns as permitted herein.

9.7
Customer's Confidential Information

The
Parties agree the Mutual Non-Disclosure Agreement executed between them prior
to the date hereof, shall be incorporated herein as if written in full herein.

    	 	6	 

    	 

    

CONFIDENTIAL
TREATMENT REQUESTED

WITH
RESPECT TO CERTAIN PORTIONS HEREOF

DENOTED
WITH “***”

 

9.8
Notice

Any
notice or other communication required or permitted hereunder shall, unless otherwise provided herein, be made in writing and
shall be delivered personally or sent by an overnight delivery or courier service, by certified or registered mail (postage prepaid),
by telegraph, by
telex, by facsimile transmission, or by email to the address first specified in this Agreement or to such other address as either
party may designate. A second notice shall be sent to Customer's legal counsel, Peter A. Levy, Esq., at Mandelbaum Salsburg PC,
3 Becker Farm Road, Suite 105, Roseland NJ 07039, USA at PLevy@lawfirm.ms. Such notice
or other communication shall be deemed given when so delivered personally, telegraphed, telexed or sent by facsimile transmission,
or, if sent by overnight delivery or courier service, the day after sent,
or if mailed, (3) days after the date of deposit in the mails. 

9.9
Other

If
any term or provision of the Agreement is declared to be invalid or unenforceable, it shall be deemed to be omitted or modified
to the extent necessary to render it valid or enforceable, and the remainder of this Agreement shall continue in full force and
effect. Failure of either party to enforce any provision hereof shall not be construed as a waiver thereof or prevent enforcement
on any other occasion or of any other provisions. Headings are for reference only; and the use of the singular and plural number
shall each be deemed to include the other as indicated by the context. All provisions in this Agreement which by their language,
nature or context are intended to survive, such as without limitation, payment limitation of liability and indemnification provisions,
shall survive any termination of this Agreement. 

9.10
Force Majeure

In
the event that either party is prevented from performing or is unable to perform any of its obligations under this Agreement (other
than a payment obligation) due to any Act of God, fire, casualty, flood, earthquake, war, strike, lockout, epidemic, destruction
of production facilities, riot, insurrection, material unavailability, electricity or other utility or telecommunication outage
or suspension of services, or any other cause beyond the reasonable control of the party (or its selected vendors, affiliates,
or the like) invoking this section, and if such party shall have used its best efforts to mitigate its effects, such party shall
give prompt written notice to the other party, its performance shall be excused, and the time for the performance shall be extended
for the period of delay or inability to perform due to such occurrences. Regardless of the excuse of Force Majeure, if such party
b not able to perform within forty-five (45) days after such event, the other party may terminate this Agreement.

	ACCEPTED AND AGREED TO:	 	 
	 	 	 
	FOR MYOS RENS TECHNOLOGIES INC.

	 	DIL

	 	 	 
	By:
	 /s/ Joseph Mannello
	 	By:
	 /s/ Dr. Volker Heinz

	Printed Name: Joseph Mannello

	 	Printed Name: Dr. Volker Heinz

	Title: CEO

	 	Title: Vorstand

	Date 11/17/16

	 	Date 18 Nov. 2016

 

 

    	 	7	 

    	 

    

CONFIDENTIAL
TREATMENT REQUESTED

WITH
RESPECT TO CERTAIN PORTIONS HEREOF

DENOTED
WITH “***”

 

EXHIBIT A

DESCRIPTION
OF THE PRODUCT

For
purposes of this Agreement, the Product shall be comprised of 100% egg yolk powder,
originating with fertilized chicken eggs.
[***]

 

    	 	8	 

    	 

    

CONFIDENTIAL
TREATMENT REQUESTED

WITH
RESPECT TO CERTAIN PORTIONS HEREOF

DENOTED
WITH “***”

 

EXHIBIT C

 

PRODUCT TESTING & ACCEPTABLE LIMITS

 

	

Parameter	Threshold
	Protein	[***]
	Fat	[***]
	Cholesterol	[***]
	Moisture	[***]
	Ash	[***]
	Arsenic	[***]
	Cadmium	[***]
	Lead	[***]
	Mercury	[***]
	Total Viable Count	[***]
	Total Coliforms	[***]
	 	[***]
	Enterobacteriaceae	[***]
	E. Coli	[***]
	L. Monocytogenes	[***]
	Mesophile sulfide reducing Clostridium spp.	[***]
	Salmonella spp.	[***]
	Yeasts	[***]
	Moulds	[***]
	Staphlyococcus (coagulase positive)	[***]

 

 

    	 	9Exhibit 10.6

 

August 30, 2016

 

Joseph Mannello

137 Jockey Hollow Road

Bernardsville, New Jersey 07924

 

Re:       Offer
of Employment as Interim Chief Executive Officer

 

Dear Joe:

 

On behalf of MYOS RENS Technology Inc. (the “Company”), I am
pleased to extend to you this offer of employment (“Offer Letter”) as the Company’s interim Chief Executive Officer. 
We are excited to have you as a part of the senior management team and your expertise is highly needed here. You will devote a
minimum of forty (40) per week to the Company and report directly to the board of directors of the Company (the “Board”).

 

You will receive an initial annual base salary of $240,000, payable in accordance
with the Company’s policies.  You will also be provided with 10,000 shares of the Company’s common stock, which
shall vest on the earlier of (i) the six month anniversary of your start date and (ii) the date that the Company hires a permanent
Chief Executive Officer. In addition, you will be eligible to receive additional equity grants in conjunction with any financing
transactions that the Company may consummate, at the sole discretion of the Board. You will be eligible to receive an annual cash
bonus in an amount up to 100% of your then current base salary (pro rated for any partial term), as may be determined by the Board
(or its compensation committee), in its sole discretion.  Annual adjustments to salary, as well as bonus and additional stock
option awards are at the sole discretion of the Board (or its compensation committee). You will continue to be entitled to receive
compensation in your capacity as an existing member of the Board.

 

You are entitled to participate in the Company’s incentive plans or
programs, including an ESOP, in each case as determined by the Board (or its compensation committee), and you shall receive the
opportunity to participate fully in the Company’s health insurance plan and any other benefits provided to all employees
of the Company. You shall be entitled to 20 vacation days and five sick days per calendar year (prorated for the remainder of 2016).

 

Your employment with the Company deems you as an employee “at will.”
This means that it is not for any specified period of time and either you or the Company can terminate your employment at any time,
and for any or no particular cause or reason.

 

This Offer Letter constitutes the sole and entire agreement of the parties
to this agreement with respect to the subject matter contained herein, and supersedes all prior and contemporaneous understandings,
agreements, representations and warranties, both written and oral, with respect to such subject matter.

 

This Offer Letter may only be amended, modified, or supplemented by an agreement
in writing signed by each party hereto, and any of the terms thereof may be waived, only by a written document signed by each party
to this Offer Letter or, in the case of waiver, by the party or parties waiving compliance.

 

This Offer Letter and your employment will be governed in all respects by
laws of the State of New Jersey.

* * * *

 

    	 		 

     

    

 

We are excited about the future of MYOS and your contribution to our success.
I look forward to receiving your acceptance of this employment offer.  To formally accept this offer, please sign in the appropriate
place below and return an executed copy of this Offer Letter to me. Please retain an executed copy of this Offer Letter for your
own records.

 

Sincerely,

 

	/s/ Christopher Pechock	 	 

Christopher Pechock

Chairman of the Compensation Committee

 

Acknowledged and agreed as of the date set forth
below:

 

	/s/ Joseph Mannello	 	 

Name: Joseph Mannello

 

Dated: 9/1/16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}]]